|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The discovery of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) has led to unprecedented clinical response in a subset of lung cancer patients carrying the sensitizing EGFR mutations (L858R or exon 19 deletion).
|
28774798 |
2017 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Evidence shows that exon 19 deletions (19del) and exon 21 Leu858Arg point mutation (L858R) of EGFR are different in response to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in advanced lung cancers.
|
29026990 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most frequent epidermal growth factor receptor (EGFR) mutations of lung cancer include exon 19 in deletion and the exon 21 L858R mutation.
|
29290255 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation).
|
29462253 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9.
|
29748615 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diagnosis of EGFR exon21 L858R point mutation as lung cancer biomarker by electrochemical DNA biosensor based on reduced graphene oxide /functionalized ordered mesoporous carbon/Ni-oxytetracycline metallopolymer nanoparticles modified pencil graphite electrode.
|
29753165 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We identified all patients with metastatic <i>EGFR</i> exon19del or L858R-mutant lung cancers treated with first/second-generation EGFR tyrosine kinase inhibitors (TKIs) with pretreatment next-generation sequencing data (MSK-IMPACT assay).
|
30045933 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Twenty resected primary lung cancers known to harbor EGFR L858R were analyzed.
|
30268468 |
2018 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.
|
30810279 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology.
|
31207149 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer.
|
31426797 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |